替拉那韦
|
|
- CAS号:
- 174484-41-4
- 英文名:
- Tipranavir
- 英文别名:
- Aptivus;ipranavir;Tipranavir;PNU-140690;Tipranavir(TPV);Tipranavir - Bio-X ?;Tipranavir Impurity 1;TIPRANAVIR (PNU-140690);Tipranavir, 10 mM in DMSO;Tipranavir(PNU-140690,Aptivus)
- 中文名:
- 替拉那韦
- 中文别名:
- 替拉那韦;替拉那韦杂质1;Tipranavir试剂;Tipranavir试剂;替拉那韦,10 MM DMSO 溶液;N-[3-[(1R)-1-[(6R)-2-羟基-4-氧代-6-苯乙基-6-丙基-5H-吡喃-3-基]丙基]苯基]-5-(三氟甲基)吡啶-2-磺酰胺;N-(3-((R)-1-((R)-4-羟基-2-氧代-6-苯乙基-6-丙基-5,6-二氢-2H-吡喃-3-基)丙基)苯基)-5-(三氟甲基)吡啶-2-磺酰胺;N-(3-((R)-1-((R)-4-羟基-2-氧代-6-苯乙N-(3-((R)-1-((R)-4-羟基-2-氧代-6-苯乙基-6-丙基-5,6-二氢-2H-吡喃-3-基)丙基)苯基)-5-(三氟甲基)吡啶-2-磺酰胺基-6-丙基-5,6-二氢-2H-吡喃-3-基)丙基)苯基)-5-(三氟甲基)吡
- CBNumber:
- CB9501005
- 分子式:
- C31H33F3N2O5S
- 分子量:
- 602.66
- MOL File:
- 174484-41-4.mol
|
|
|
替拉那韦化学性质
-
熔点:
-
86-890C
-
|
-
比旋光度:
-
D +20° (ethanol)
-
|
-
沸点:
-
712.3±70.0 °C(Predicted)
-
|
-
密度:
-
1.313±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
-20°C Freezer
-
|
-
溶解度:
-
Methanol (Slightly)
-
|
-
形态:
-
Solid
-
|
-
酸度系数(pKa):
-
4.50±1.00(Predicted)
-
|
-
颜色:
-
White to Pale Yellow
-
|
-
BCS Class:
-
2
-
|
-
InChIKey:
-
SUJUHGSWHZTSEU-FYBSXPHGSA-N
-
|
-
SMILES:
-
C1(S(NC2=CC=CC([C@H](C3=C(O)C[C@](CCC4=CC=CC=C4)(CCC)OC3=O)CC)=C2)(=O)=O)=NC=C(C(F)(F)F)C=C1
-
|
替拉那韦性质、用途与生产工艺
替拉那韦,西药名。常用剂型有胶囊剂等。为抗病毒药。合用利托那韦对具有病毒复制、并已治疗时间很长或感染HIV-1面又耐多种蛋白酶抑制剂的成年患者进行治疗。
Tipranavir (PNU-140690) 有效抑制 HIV-1 蛋白酶 酶活性和二聚化,对抗多种蛋白酶抑制剂(PI)的HIV-1分离株具有有效的活性,IC50 为 66-410 nM。
IC50: 66-410 nM (HIV-1 isolates)
Tipranavir (PNU-140690) inhibits the enzymatic activity of HIV-1 protease, blocks the dimerization of protease subunits, and exerts potent activity against a wide spectrum of wild-type and multi-PI-resistant HIV-1 variants. When a mixture of 11 multi-PI-resistant (but TPV-sensitive) clinical isolates (HIV
11MIX
), which include HIV
B
and HIV
C
, is selected against Tipranavir, HIV
11MIX
rapidly (by 10 passages [HIV
11MIX
P10
]) acquires high-level Tipranavir (PNU-140690) resistance and replicates at high concentrations of Tipranavir (PNU-140690). cHIV
B
I54V
and cHIV
B
I54V/V82T
are significantly resistant to Tipranavir (PNU-140690), with IC
50
s of 2.9 and 3.2 μM, respectively, which are 11- and 12-fold increases in comparison to the IC
50
against cHIV
B
, respectively.
Tipranavir (PNU-140690) is administered orally twice daily and must be given in combination with low-dose ritonavir (RTV) to boost Tipranavir bioavailability. In Tipranavir/r-cotreated mice, the Tipranavir (PNU-140690) abundance in the liver, spleen, and eyes is significantly higher than that in mice treated with Tipranavir alone. Tipranavir (PNU-140690) metabolites accounts for 31 and 38% in the serum and liver in the Tipranavir-alone group. In Tipranavir (PNU-140690) and Tipranavir (TPV/r)-cotreated mice, only 1 and 2% of metabolites are detected in the serum and liver. Sprague-Dawley rats are administered a single dose of [
14
C]Tipranavir (PNU-140690) with coadministration of RTV. The most abundant metabolite in feces is an oxidation metabolite. In urine, no single metabolite is found to be significantly present.
替拉那韦
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2025/05/22 | HY-15148 | 替拉那韦 Tipranavir | 174484-41-4 | 1mg | 950元 |
2025/05/22 | HY-15148 | 替拉那韦 Tipranavir | 174484-41-4 | 5mg | 3300元 |
替拉那韦
生产厂家
全球有 124家供应商
替拉那韦国内生产厂家
174484-41-4, 替拉那韦 相关搜索:
- Antiviral Agents
- Pharmaceuticals
- Intermediates & Fine Chemicals
- Inhibitors
- All Inhibitors
- 抑制剂
- 药靶配体
- 抗病毒类
- 医药中间体
- Tipranavir试剂
- Tipranavir试剂
- 替拉那韦,10 MM DMSO 溶液
- N-(3-((R)-1-((R)-4-羟基-2-氧代-6-苯乙N-(3-((R)-1-((R)-4-羟基-2-氧代-6-苯乙基-6-丙基-5,6-二氢-2H-吡喃-3-基)丙基)苯基)-5-(三氟甲基)吡啶-2-磺酰胺基-6-丙基-5,6-二氢-2H-吡喃-3-基)丙基)苯基)-5-(三氟甲基)吡
- N-(3-((R)-1-((R)-4-羟基-2-氧代-6-苯乙基-6-丙基-5,6-二氢-2H-吡喃-3-基)丙基)苯基)-5-(三氟甲基)吡啶-2-磺酰胺
- 替拉那韦杂质1
- N-[3-[(1R)-1-[(6R)-2-羟基-4-氧代-6-苯乙基-6-丙基-5H-吡喃-3-基]丙基]苯基]-5-(三氟甲基)吡啶-2-磺酰胺
- 替拉那韦
- 174484-41-4
- Tipranavir - Bio-X ?
- Tipranavir, 10 mM in DMSO
- N-{3-[(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
- Tipranavir Impurity 1
- ipranavir
- N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
- N-[3-[(1R)-1-[(2R)-4-HYDROXY-6-OXO-2-(2-PHENYLETHYL)-2-PROPYL-3H-PYRAN-5-YL]PROPYL]PHENYL]-5-(TRIFLUOROMETHYL)PYRIDINE-2-SULFONAMIDE
- TIPRANAVIR (PNU-140690)
- Tipranavir(TPV)
- 2-PyridinesulfonaMide,N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoroMethyl)-
- Tipranavir(PNU-140690,Aptivus)
- Tipranavir
- N-[3-[(1R)-1-[(6R)-2-Hydroxy-4-oxo-6-phenethyl-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
- N-[3-[(1R)-1-[(6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
- Aptivus
- PNU-140690